metaPreg - Pregabalin (Epilepsy) during pregnancy

Pregabalin (Epilepsy) updated on 12-01-2025

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)	5.55 [0.89, 34.62]	0%	3 studies	155	13	not evaluable	ROB	-
Major congenital malformations	5.55 [0.89, 34.62]	0%	3 studies	155	13	not evaluable	ROB	-
Growth parameters and prematurity
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
2 non statistically significant endpoints reported in only one study
Maternal consequences
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
1 non statistically significant endpoints reported in only one study
Intrauterine deaths
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
1 non statistically significant endpoints reported in only one study
Neuro-developmental disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
ASD (Autism spectrum disorder): Diagnosis	0.88 [0.08, 9.24]	28%	2 studies	503	54	not evaluable	ROB	-
ASD (Autism spectrum disorder): Diagnosis/Risk	0.88 [0.08, 9.24]	28%	2 studies	503	54	not evaluable	ROB	-
ADHD (Attention deficit hyperactivity disorder): Diagnosis	2.35 [0.01, 624.13]	92%	2 studies	929	54	not evaluable	ROB	-
ADHD (Attention deficit hyperactivity disorder): Diagnosis/Risk	2.35 [0.01, 624.13]	92%	2 studies	929	54	not evaluable	ROB	-
Neuro-developmental disorders (as a whole)	3.08 [1.50, 6.33]	-	1 study	122	37	not evaluable	ROB	5.61 [2.36; .]
4 non statistically significant endpoints reported in only one study